Clicky

Health

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
933 574 Jane

– Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains – Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA /…

  • Jane
  • 0
  • 0

Empower Clinics Signs Partnership with One of North America’s Largest Terminal Operators to Provide COVID Testing Services
600 600 Todd

Partnership with CERES Terminals Canada Supporting the safe return of the cruise ship industry to Vancouver with more than 1,200,000 passengers anticipated for 2022 VANCOUVER, BC / ACCESSWIRE / February 10, 2022 / EMPOWER CLINICS…

  • Todd
  • 0
  • 0

Panacea Announces Launch of New Product COVID CBDA(TM)
1500 600 Todd

“Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2” the researchers stated in the…

  • Todd
  • 0
  • 0

Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who’ve Exhausted All Approved Therapies
440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / January 19, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the…

  • Merci
  • 0
  • 0

Eyam Vaccines and Immunotherapeutics Welcomes New Board Members and Scientific Advisors
594 280 admin

VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / Eyam Vaccines and Immunotherapeutics is pleased to publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the Board of Directors, and the…

Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / January 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (“ Relief “), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need,…

  • Merci
  • 0
  • 0

Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / December 30, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the…

  • Merci
  • 0
  • 0

Empower Clinics Kai Medical Laboratory Secures COVID-19 Testing Contract For Large Gaming Event In Las Vegas
270 50 Todd

Kai Medical Laboratory to Provide Over 6,000 Rapid Antigen and PCR COVID-19 Tests VANCOUVER, BC / ACCESSWIRE / December 13, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company –…

  • Todd
  • 0
  • 0

Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection
150 150 Robert

SAN DIEGO, CA / ACCESSWIRE / December 7, 2021 / Ainos, Inc. (“we”, “our”, or the “company”), (OTC PINK:AIMD), a diversified healthcare company engaged in the discovery and development of pharmaceutical, medical devices and biotech…

  • Robert
  • 0
  • 0

Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that…

  • Merci
  • 0
  • 0